Evidence map›Paper›PMID 23869564›Full record

ArticleBiochemistry2013

Biological and structural evaluation of 10R- and 10S-methylthio-DDACTHF reveals a new role for sulfur in inhibition of glycinamide ribonucleotide transformylase.

Stephen Connelly, Jessica K DeMartino, Dale L Boger, Ian A Wilson

Open access · greenAbstract read
In one paragraph

Article in Biochemistry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Saudi journal of biological sciences · 2017
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Stephen ConnellyDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States.
Jessica K DeMartino
Dale L Boger
Ian A Wilson
Scripps Research Institute · US

Funding

X RAY CRYSTALLOGRAPHY--ENZYME AND ENZYME-INHIBITOR COMPLEXESP01CA063536 · NCI · SCRIPPS RESEARCH INSTITUTE · PI WILSON, IAN A · 1994 to 2005
$6.0M
NCI NIH HHS P01 CA063536
6 · The paper itself

Abstract

Glycinamide ribonucleotide transformylase (GAR Tfase) is a folate-dependent enzyme in the de novo purine biosynthesis pathway, which has long been considered a potential target for development of anti-neoplastic therapeutics. Here we report the biological and X-ray crystallographic evaluations of both independent C10 diastereomers, 10S- and 10R-methylthio-DDACTHF, bound to human GAR Tfase, including the highest-resolution apo GAR Tfase structure to date (1.52 Å). Both diastereomers are potent inhibitors (Ki = 210 nM for 10R, and Ki = 180 nM for 10S) of GAR Tfase and exhibit effective inhibition of human leukemia cell growth (IC₅₀ = 80 and 50 nM, respectively). Their inhibitory activity was surprisingly high, and these lipophilic C10-substituted analogues show distinct advantages over their hydrophilic counterparts, most strikingly in retaining potency in mutant human leukemia cell lines that lack reduced folate carrier protein activity (IC₅₀ = 70 and 60 nM, respectively). Structural characterization reveals a new binding mode for these diastereoisomers, in which the lipophilic thiomethyl groups penetrate deeper into a hydrophobic pocket within the folate-binding site. In silico docking simulations of three other sulfur-containing folate analogues also indicate that this hydrophobic cleft represents a favorable region for binding lipophilic substituents. Overall, these results suggest sulfur and its substitutions play an important role in not only the binding of anti-folates to GAR Tfase but also the selectivity and cellular activity (growth inhibition), thereby presenting new possibilities for the future design of potent and selective anti-folate drugs that target GAR Tfase.

Indexed as

Models, MolecularAntimetabolites, AntineoplasticApoproteinsBinding SitesCarbon-Nitrogen LigasesCell Line, TumorCell ProliferationEnzyme InhibitorsHumansInhibitory Concentration 50LeukemiaMolecular ConformationMolecular Docking SimulationNeoplasm ProteinsPeptide FragmentsPhosphoribosylaminoimidazolecarboxamide Formyltransferase10-methylthio-DDACTHFAntimetabolites, AntineoplasticApoproteinsCarbon-Nitrogen LigasesEnzyme InhibitorsGART protein, humanNeoplasm ProteinsPeptide FragmentsPhosphoribosylaminoimidazolecarboxamide FormyltransferasePhosphoribosylglycinamide FormyltransferaseRecombinant ProteinsTetrahydrofolates

Identifiers

PMID23869564
PMCPMC3823235
OpenAlexW2062489269

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.